Myriad Genetics, Inc.
MYGN
$4.81
-$0.34-6.60%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -1.56% | 0.21% | 3.83% | 7.38% | 11.21% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -1.56% | 0.21% | 3.83% | 7.38% | 11.21% |
| Cost of Revenue | -1.70% | -3.74% | -0.81% | 3.19% | 6.77% |
| Gross Profit | -1.50% | 1.97% | 5.90% | 9.28% | 13.23% |
| SG&A Expenses | -4.10% | -2.49% | -1.93% | -0.07% | -0.16% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.59% | -1.25% | 0.44% | 3.54% | 4.41% |
| Operating Income | 22.87% | 13.85% | 25.85% | 22.34% | 34.01% |
| Income Before Tax | -220.18% | -264.75% | -168.39% | 46.11% | 52.94% |
| Income Tax Expenses | -848.72% | -4,033.33% | -1,692.86% | -2,733.33% | 254.55% |
| Earnings from Continuing Operations | -187.43% | -245.26% | -154.64% | 56.78% | 51.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -187.43% | -245.26% | -154.64% | 56.78% | 51.65% |
| EBIT | 22.87% | 13.85% | 25.85% | 22.34% | 34.01% |
| EBITDA | 47.19% | 22.49% | 63.88% | 53.14% | 65.32% |
| EPS Basic | -181.58% | -233.51% | -137.30% | 60.45% | 56.19% |
| Normalized Basic EPS | 15.56% | 12.22% | 27.06% | 27.51% | 42.01% |
| EPS Diluted | -181.02% | -232.38% | -136.56% | 60.47% | 56.18% |
| Normalized Diluted EPS | 15.56% | 12.22% | 27.06% | 27.51% | 42.01% |
| Average Basic Shares Outstanding | 2.15% | 2.97% | 4.99% | 7.18% | 9.52% |
| Average Diluted Shares Outstanding | 2.15% | 2.97% | 4.99% | 7.18% | 9.52% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |